Table 1.
Expression of chemokine receptors by peripheral blood T cells in MS patients
| Receptors | Double-positive cells, %
|
||
|---|---|---|---|
| Controls | RR MS | Progressive MS | |
| CD3+ CCR3+ | 1.4 ± 0.3 (20) | 2.0 ± 0.6 (14) | 2.1 ± 0.3 (20) |
| CD3+ CCR4+ | 9.0 ± 1.1 (6) | 7.1 ± 0.6 (14) | 9.6 ± 2.7 (7) |
| CD3+ CCR5+ | 7.9 ± 0.8 (20) | 9.9 ± 1.3 (14) | 13.1 ± 1.4** (20) |
| CD3+ CCR6+ | 8.6 ± 1.3 (9) | Not tested | 9.2 ± 0.7 (10) |
| CD3+ CXCR3+ | 9.1 ± 1.1 (20) | 14.4 ± 1.9* (14) | 14.8 ± 1.5** (20) |
| CD3+ CXCR4+ | 47.1 ± 8.1 (9) | Not tested | 30.9 ± 5.3 (10) |
PBMC from control healthy donors, relapsing–remitting (RR) MS, and progressive MS patients were separated and a three-step staining procedure, with mouse anti-chemokine receptor mAb followed by FITC-conjugated goat anti-mouse IgG and then PE-labeled anti-CD3 mAb, was performed as described in the text. Two-color flow cytometry was performed, and percentage of double-positive cells was analyzed and presented as mean ± SEM, with the number of patients in parentheses. ∗, P < 0.05 vs. controls; ∗∗, P < 0.005 vs. controls.